V1b Vasopressin R/AVPR1B Antibody

Product Discontinued

V1b Vasopressin R/AVPR1B Antibody Summary

• Immunogen: Synthetic peptide, corresponding to amino acids 300-350 of Human AVP Receptor V3.
• Clonality: Polyclonal
• Host: Rabbit
• Gene: AVPR1B
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry/ Immunofluorescence 1:50-1:200
  • Western Blot 1:500-1:1000
• Theoretical MW: 47 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS (pH 7.2)
• Preservative: 0.05% Sodium Azide
• Concentration: 1.0 mg/ml
• Purity: Immunogen affinity purified

Alternate Names for V1b Vasopressin R/AVPR1B Antibody

• Antidiuretic hormone receptor 1b
• arginine vasopressin receptor 1B
• AVPR V1b
• AVPR V3
• AVPR1B
• AVPR3
• AVPR3arginine vasopressin receptor 3
• pituitary vasopressin receptor 3
• V1b Vasopressin R
• V1b VasopressinR
• V1bR
• vasopressin V1b receptor
• Vasopressin V3 receptor
• VPR3

Background

Vasopressin (AVP), the antidiuretic hormone, is a cyclic nonpeptide that is involved in the regulation of body fluid osmolality. AVP mediates its effects through a family of G protein coupled receptors, the vasopressin receptors type V1a, V2 and V3 (also designated V1b). The AVP receptor V1a is responsible for several functions, including blood vessel constriction, liver glycogenolysis and platelet adhesion. It is detected as an 85-90 kDa full length protein and a 46 kDa protein, which results from proteolytic cleavage of its amino terminus. The V1a receptor is coupled to Gq/11 protein, which increases the intracellular calcium concentration. The human AVP receptor V2 gene maps to chromosome Xq28 and is expressed in lung and kidney. Mutations in the V2 receptor result in nephrogenic diabetes insipidus (NDI), a rare X-linked disorder characterized by the inability of the kidney to concentrate urine in response to AVP. The AVP Receptor V2 activates the Gs protein and the cyclic AMP second messenger system. The AVP receptor V3 is preferentially expressed in the pituitary and stimulates the release of adrenocorticotropic hormone (ACTH) in response to AVP by mobilizing intracellular calcium stores. AVP receptor antagonists may have potential therapeutic effects in hypertension, congestive heart failure, nephrotic syndrome and ACTH-secreting tumors.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: AVPR1B
• Entrez:
  • 553(Human)
• Uniprot:
  • P47901(Human)